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ExosomeEpidermal growth factor receptor (EGFR) genemutations are strongly associatedwith lung adenocarcinoma and
favorable response to EGFR tyrosine kinase inhibitor. The mutated EGFR proteins (EGFRs) are hyper-
phosphorylated and refractory to receptor down-regulation. To address the discrepancy between hyper-
phosphorylation and lack of down-regulation of mutant EGFRs, we have examined the expression of EGFR neg-
ative regulators in non-small cell lung cancer (NSCLC) cell lines. We found that NSCLC cell lines expressing mu-
tant EGFRs often had low expression of various negative regulators for EGFR. Among them, tumor suppressor
CD82 was up-regulated by wild type (WT) EGFR but down-regulated by mutant EGFRs. Reconstitution of CD82
exerted stronger suppressive effects on mutant EGFRs than on WT EGFR. Active exportation of CD82 through
the exosome was one of the mechanisms involved in achieving the overall CD82 down-regulation in mutant
EGFR-expressing lung cancer cell lines. Over-expression of mutant EGFR protein frequently occurred in the
lung cancer tissues of mutant EGFR-transgenic mice and also associated with CD82 down-regulation. Immuno-
blot analyses on the tumor tissues from23 lung adenocarcinomapatients (12withWTEGFR, and 11withmutant
EGFRs) also identiﬁed signiﬁcantly stronger down-regulation of CD82 in tumors with mutant EGFRs than WT.
Our data indicate that CD82 down-regulation could be a critical step involved in the EGFR over-expression and
the stronger tumorigenic activity triggered by EGFR mutations. Up-regulation of the CD82 level may become a
promising new treatment strategy for lung adenocarcinoma.
© 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epidermal growth factor receptor (EGFR) participates in various cel-
lular functions and abnormal EGFR signaling is involved in many;LAC,lungadenocarcinoma;Del,
a; GAK, cyclin G-associated ki-
se C; SP-A, surfactant protein A;
-aza-dC, 5-aza-deoxy-cytidine;
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icle under the CC BY-NC-ND licensemalignant diseases [1,2]. EGFR mutations in the kinase domain fre-
quently occur in lung adenocarcinoma (LAC) among East Asians [3,4].
The L858R mutation and deletions (Del) in exon 19 are the major
EGFR mutations [3–7]. Mutant EGFR proteins (EGFRs) are strongly
tyrosine-phosphorylated in the absence of ligands [8,9]. Phosphoryla-
tion of wild type (WT) EGFR leads to subsequent internalization,
ubiquitination, and degradation [1]. In contrast, mutated EGFR is resis-
tant to down-regulation albeit their hyper-phosphorylation status [8,
10,11]. Agreeing with these observations, EGFR mutations are closely
associated with EGFR over-expression in LAC tissues [3]. Thus, mutant
EGFRs are supposed to exert stronger tumorigenic activity than WT
EGFR [12]. However, the detailed molecular mechanism of mutant
EGFRs' stronger tumorigenic ability remains to be elucidated.
To address the discrepancy between hyper-phosphorylation and
lack of down-regulation of mutant EGFRs, we have examined the ex-
pression of various negative regulators for EGFR in lung cancer cell(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
DNA and RNA oligonucleotides used in this study.
No. Name Oligonucleotides sequences
1 CD82 cloning 5′-GCGAAGCTTACCATGGGCTCAGCCTGTATCAAAGTCAC &
5′-GCGCTCGAGATGTACTTGGGGACCTTGCTGTAG
2 SP-A promoter 5′-GCGCACGCGTGGACACTATTGGGGCATTGGGTAC &
5′-GCGAAGCTTCAGAGCCTCCAGCTGCTTGGGTCTC
3 BGH poly A seq 5′-GCCGCTAGCTCAGCCTCGACTGTGCC &
5′-GCGTCTAGACTCAGAAGCCATAGAGCC
4 Insulator I 5′-CGCGGGCCCGGGACAGCCCCCCCCCAAAG &
5′-GCGTCTAGAGACTCCGTCCTGGAGTTGG
5 Insulator II 5′-GGTCCGCGGGGGACAGCCCCCCCCCAAAG &
5′-CGCGGGCCCGACTCCGTCCTGGAGTTGG
6 CD82 qRT-PCR 5′-GTGAGGAAGGGCTTCTGCGAG &
5′-GTACTTGGGGACCTTGCTGTAG
7 GAPDH qRT-PCR 5′-CGGAGTCAACGGATTTGGTCGTAT-3′ &
5′-AGCCTTCTCCATGGTGGTGAAGAC-3′
8 Actin qRT-PCR 5′-CCTGGCACCCAGCACAAT &
5′-TCCTGCTTGCTGATCCACATC
9 CD82 siRNA 5′-GUGUAUCAAAGUCACCAAA &
5′-UUUGGUGACUUUGAUACAG
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phoma (c-Cbl, the EGFR ubiquitin ligase) [13], cyclin G-associated ki-
nase (GAK, an endocytosis regulator) [14], and CD82 [15–18]. We
found that lung cancer cell lines expressing mutant EGFRs frequently
had low expression of one or several of the above three proteins.
Among them, the tumor suppressor CD82 was up-regulated by WT
EGFR but down-regulated by mutant EGFRs, which is intriguing.
CD82, amember of the teraspanin family, is a cancermetastasis sup-
pressor and is often down-regulated in cancers [15–18]. Moreover,
CD82 expression is correlated with a good prognosis in non-small cell
lung cancer (NSCLC) patients [19]. CD82's anti-metastatic ability is
attributed to its interaction with integrin molecules [20–23]. CD82 in-
teractswith Duffy antigen receptor for chemokines (DARC) on endothe-
lial cells and causes the growth inhibition of the CD82-expressing tumor
cells [24]. Additionally, CD82 interacts with EGFR and c-Met to suppress
the receptor-induced lamellipodia formation [25]. CD82 enhances EGF-
induced EGFR internalization,which ismediated throughprotein kinase
C (PKC)α and ganglioside-dependent mechanisms [25–27]. A recent
study shows that CD82 reduces the level of ubiquitylation of EGFR
upon heparin-binding EGF (HB-EGF) or amphiregulin stimulation and
alters the postendocytic trafﬁcking of EGFR [28].
In this study, we found that EGFR over-expression was associated
with a marked reduction of CD82 in (1) NSCLC cells expressing mutant
EGFRs, (2) NSCLC cells with endogenous EGFR mutations, (3) lung can-
cer tissues derived from mutant EGFR-transgenic (Tg) mice, and
(4) tumor tissues of LAC patients with EGFRmutation. Our data indicat-
ed that down-regulation of CD82 could be a mechanism involved in the
mutant EGFR over-expression in LAC cells.
2. Material and methods
2.1. Cell cultures and transfection
Five human NSCLC cell lines (H1299, HCC1975, HCC1650, HCC827
and PE089) were used in this study. The H1299 cell line is established
from a patient with lung carcinoma. The PE089, H1650, H1975,
HCC827 cell lines (the latter three were provided by Dr. Tsu-An Hsu
from the Institute of Biotechnology and Pharmaceutical Research, Na-
tional Health Research Institutes, Taiwan) are derived from patients
with LAC. H1299 cells express wild type (WT) EGFR; the H1975 cell
line has L858R/T790M double mutations; and H1650, PE089, and
HCC827 cells all have EGFR exon 19 deletion (Del). H1299 deriva-
tives were established by transfection with an empty pcDNA4/TO/
myc-His vector (Invitrogen; Carlsbad, CA) or with a vector contain-
ing WT-EGFR, EGFR-L858R, or EGFR-Del coding sequence. The
transfected cells were subjected to 500 μg/ml of zeocin (Invitrogen)
selection for one week to establish permanently transfected cells as
previously described [8]. H1299-EGFR, H1299-L858R, and H1299-
Del cells were combined in pools of drug-resistant colonies express-
ing the respective receptor, as conﬁrmed by immunoblotting assays,
to avoid clonal variations. H1299 and its derivatives were cultured in
RPMI-1640 medium supplemented with 10% fetal calf serum (FCS)
plus penicillin and streptomycin [8]. H1650, H1975, and HCC827
cells were cultured in the same media as H1299 cells. PE089 cell
line was cultured in DMEM basal medium supplemented with 10%
FCS plus penicillin and streptomycin [29]. Transient transfections of
cells were performed using the Lipofectamine-2000 reagent
(Invitrogen) according to the manufacturer's instruction.
2.2. Construction of DNA vectors
CD82-coding sequencewas PCR-ampliﬁed using a cDNA pool pre-
pared from H1299 cells. The DNA fragment was enzyme-digested
and inserted into a pCR3.1 vector (Invitrogen) between Hind III and
Xho I sites with a carboxy-terminal Flag tag. To construct the
vectors for Tg mice with mutated EGFR, the backbone plasmid usedwas the pcDNA4 mutant EGFR-expressing vector described previ-
ously [8]. Surfactant protein A (SP-A) promoter was PCR ampliﬁed
using the genomic DNA of H1299 cells as the template. The bovine
growth hormone (BGH) poly-adenylation sequence was PCR ampli-
ﬁed using the pCR3.1 vector as a template. The chicken β-globin in-
sulator sequence was kindly provided by Dr. Felsenfeld (National
Institute of Diabetes and Digestive and Kidney Disease, MD, USA)
[30]. All the PCR-derived DNA fragments inserted into the Tg vector
were sequence-veriﬁed. The sequences of the oligonucleotides
used in this study were listed in the Table 1.
2.3. Establishment of Tg mice with mutant EGFRs
The 8.9 kilo-based Tg cassette was released from the construction
vector between Sca I and Pme I sites for mouse pronuclear injections.
The micro-injections of C57BL/6 fertilized eggs were performed in the
Level Biotechnology Inc. (Taipei, Taiwan). Successful injections were
veriﬁed by positive identiﬁcation of the human EGFR gene in the Tg
mouse tail DNA through Southern blot analyses and PCR genome-
typing. Mutant EGFR-Tg mice were sacriﬁced at indicated ages and
were examined for the presence of any tumor-like lesions. Portions of
the lung tissues, either with orwithout tumor formation,were snap fro-
zen and stored at−80 °C deep freezer for future DNA, RNA and protein
extractions. The remaining lung tissues were ﬁxed in neutral formalin
for parafﬁn section preparations. All experimental procedures using an-
imals were approved by the Institutional Animal Care and Use Commit-
tees of National Health Research Institutes (NHRI).
2.4. Patient materials
Fresh frozen tumor and paired non-tumor lung tissue specimens of
23 LAC patients receiving surgical resection at Chang Gung Memorial
Hospital (CGMH) and with signed informed consent were obtained
from the tissue bank of CGMH. All of the specimens were snap frozen
soon after resection and stored at −80 °C. Only tumor tissues with
higher than 70% tumor content were included for this study. The speci-
mens were used for protein extraction and immunoblot analysis to ex-
amine the expression of EGFR and CD82 in these specimens. The study
protocol has been reviewed and approved by the Institutional Review
Boards of CGMH and NHRI.
2.5. RNA extraction and complementary DNA (cDNA) synthesis for quanti-
tative polymerase chain reaction (Q-PCR)
Fresh frozen tumor and paired non-tumor lung tissues from Tgmice,
control non-Tgmice, or LAC patients were used as startingmaterials for
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Onemicroliter of the resulting cDNAwas used for further PCR reactions.
Q-PCRwas performed using LightCycler FastStart DNAMasterplus SYBR
Green I kit (Roche Molecular Biochemicals, Indianapolis, IN) in the
LightCycler instrument with a total volume of 20 μl in the LightCycler
glass capillaries. The reaction program was: initial heating to 95 °C for
10min followed by 29 PCR cycles of heating to 95 °C for 10 s, incubation
for 10 s at the annealing temperature speciﬁc for the use of primer, and
incubation for 25 sections at 72 °C. A melting curve analysis was con-
ducted after every Q-PCR to identify the PCR product and to detect the
possible presence of contaminating products. Each sample was normal-
ized on the basis of itsβ-actinmRNA content. The relative quantiﬁcation
was determined by using the comparative CT method.2.6. Tissue protein extraction
The tissue proteins were prepared by homogenizing the tissues in
lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% Triton X-100, 0.5%
deoxycholate, 0.1% SDS, 2 μg/ml leupeptin, 5 μg/ml aprotinin, 1 mM
PMSF, 1 mM dithiothreitol, and 1 mM Na3VO4) using the MagNA Lyser
Green Beads protocol (Roche Diagnostics, Indianapolis, IN) and stored
in−80 °C for further characterization.2.7. Antibodies and reagents
The anti-EGFR, EGFR-L858R, EGFR-Del, and phospho-EGFR (pEGFR;
Y1068 and Y1045) antibodies were purchased from Cell Signaling Tech-
nology (Beverly, MA). The anti-CD82, anti-GAPDH, and anti-GAK anti-
bodies were purchased from AbCam (Cambridge, UK). The anti-c-Cbl
and peroxidase-conjugated secondary antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-Flotillin 1
and gp78 antibodies were purchased from GeneTex, Inc. (Irvine, CA).
EGFwas purchased from Sigma-RBI (Natick, MA). The anti-β-actin anti-
body, small interference RNA (siRNA) against CD82, and other chemical
inhibitors were purchased from Sigma-Aldrich (St. Louis, MO). Geﬁtinib
was provided by the Institute of Biotechnology and Pharmaceutical Re-
search, NHRI, Taiwan.2.8. Cell extract, exosome fraction preparation, and immunoblot analyses
Cell extract was prepared as described previously [32]. Exosome
preparation was performed by differential ultra-centrifugation as
previously described [33]. Twenty-four hours before harvesting the
samples (cells and conditioned media), the cells were fed with
fresh culture medium. The exosome-enriched fractions from the
conditioned media were recovered with 70,000 g centrifugation
and were re-suspended in the lysis buffer. Immunoblot analysis
was performed as described previously [8]. For the paired compari-
son of cellular and exosome proteins, 50 μg of any individual cellular
extract was subjected to analyses. The amount of exosome proteins
to be examined was adjusted according to the proportion of the cor-
responding cellular extract used in the same analysis. The relative
ratio (in term of recovered protein) of paired exosome/cell samples
subjected to immunoblot analyses is 3:1 to reveal the less abundant
proteins in the exosome fractions.2.9. Immuno-histochemical (IHC) stain
IHC stains were performed for EGFR, EGFR-L858R and EGFR-Del and
SP-C on the Tg mice lung tumor tissue on a formalin ﬁxed parafﬁn sec-
tion. The detailed procedures were the same as previously described
[31]. The dilutions for the antibodies were: 1:150 for EGFR, EGFR-
L858R and EGFR-Del, respectively and 1:1000 for SP-C.3. Results
3.1.Wild type andmutated EGFRs have opposite effects on CD82 expression
in H1299 cells
Previously we have established NSCLC H1299 cell lines permanently
expressing WT EGFR (H1299-EGFR), L858R mutant (H1299-L858R), or
exon 19 deletion mutant (H1299-Del) [8]. We found that c-Cbl and
GAK were slightly increased in H1299-L858R and H1299-Del cells in
comparisonwith H1299-EGFR cells and H1299-Vec (vector control). In-
terestingly, the expression of CD82 was markedly increased in H1299-
EGFR cells, but decreased in H1299-L858R and H1299-Del cells in com-
parison with H1299-Vec (Fig. 1a). CD82mRNA expression levels varied
but were comparable among H1299 cell derivatives (Fig. 1b). The re-
sults indicated that the differential CD82 expression could be controlled
at the post-transcriptional level. Geﬁtinib, an EGFR kinase inhibitor, did
not reverse the CD82 expression patterns (Fig. 1c), indicating that the
up- and down-regulations of CD82 in H1299 derivatives were not di-
rectly caused by aberrant signaling immediately downstreamofmutant
EGFRs.
3.2. NSCLC cells harboring EGFR mutation also show low levels of CD82
CD82 expression was examined in NSCLC cells with endogenous
EGFR mutations. In comparison to H1299 cells (WT EGFR), H1975
(L858R/T790M double mutations), H1650 (exon 19 Del), PE089 (exon
19 Del), and HCC827 (exon 19 Del) all showed lower levels of CD82 ex-
pression (Fig. 1d). H1975, PE089, and HCC827 cells also had lower CD82
mRNA expression, but H1650 cells had high CD82 mRNA expression
(Fig. 1e). Since CD82 expression is subjected to epigenetic regulations
in myeloma cell lines [34], we have treated NSCLC cells with 5-aza-
deoxy-cytidine (5-aza-dC), a DNA demethylation agent, which did not
affect CD82 protein expression (Fig. 1f). Trichostatin (TsA), a histone
deacetylase inhibitor, was also used to treat NSCLC cells. TsA caused
slightly increased CD82 expression in H1975 cells but not in other
cells (Fig. 1f). The above data indicated that CD82 expression in these
NSCLC cells wasmainly controlled bymechanisms other than epigenet-
ic regulation.
3.3. Suppression of CD82 promotes EGFR expression in H1299 cells
The up-regulation of CD82 by WT EGFR was intriguing (Fig. 1a).
H1299-vector and H1299-EGFR cells were both treated with or without
a small interference RNA against CD82 (siCD82). CD82 knockdown
increased the expression of EGFR in H1299-vector cells and partially
prevented the down-regulation of EGFR upon EGF stimulation (Fig. 2a).
Because of the over-expression of EGFR, ligand-induced EGFR down-
regulation was less evident in H1299-EGFR cells. But CD82 knockdown
in H1299-EGFR cells also alleviated ligand-induced EGFR down-
regulation and retained stronger EGFR phosphorylation (Fig. 2a). This re-
sult indicated that CD82 was functional in down-regulation of EGFR sig-
naling in both H1299-vector and H1299-EGFR cells.
3.4. Reconstitution of CD82 reduces mutant EGFR expression in H1299 cells
Low CD82 levels in NSCLC cells expressing mutant EGFR suggested
that lacking CD82 might be beneﬁcial to mutant EGFR-induced cell
growth. We reconstituted CD82 expression in H1299-L858R or
H1299-Del cells and found that CD82 expression signiﬁcantly decreased
the protein and phosphorylation levels of mutant EGFRs (Fig. 2b). In ad-
dition, CD82 greatly decreased the expression of mutant EGFRs, but the
suppressive effect was less evident on the WT receptor (Fig. 2c). These
results indicated that mutant EGFRs were more sensitive to the CD82-
mediated negative regulation. Geﬁtinib treatment reduced the phos-
phorylation of EGFRs but did not reverse the down-regulation of WT
Fig. 1. CD82 expression levels are decreased in NSCLC cells harboringmutant EGFRs. (a and d) Immunoblot analyses for c-Cbl, GAK and CD82 expression levels in the cell extracts from the
regularly cultured H1299 derivatives (panel a), and from the 5 NSCLC cells (panel d). (b and e) The gel electrophoresis assays presented the CD82 and actinmRNA levels by RT-PCR in the
H1299 derivatives (panel b) and the 5 NSCLC cells (panel e). The CD82/actinmRNA ratioswere calculated from the results of quantitative RT-PCR. (c) Immunoblot analyses for the expres-
sion levels of phosphorylated EGFR (pEGFR), EGFR and CD82 in the cell extracts of regularly cultured H1299 derivatives (with or without geﬁtinib treatment for 24 h). (f) Immunoblot
analyses for the expression levels of EGFR and CD82 in the cell extracts prepared from the 5 NSCLC cells treatedwith 5-aza-dC (10 μM, 72 h) or TsA (100 nM, 24 h). The asterisks indicated
a cross-reactive protein recognized by the anti-CD82 antibody.
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regulation is independent of the kinase phosphorylation (Fig. 2c).
3.5. Gp78/proteasome and lysosome-mediated degradation pathways do
not participate in the CD82 down-regulation in mutant EGFR-expressing
NSCLC cells
We then examined the potential mechanisms for CD82 down-
regulation in mutant EGFR-expressing NSCLC cells. E3 ubiquitin ligaseFig. 2. Suppression of CD82 increases EGFR expression and reconstitution of CD82efﬁciently sup
with control siRNA or CD82 siRNA (sicontrol and siCD82). The transfected cells were then trea
phorylation) of these samples were determined by immunoblot analyses. (b) H1299-L858R an
indicated proteins in the transfected cells and control H1299 derivatives were examined by im
with the CD82 expressing vector. The transfected cells were treated with or without geﬁtinib (
these samples were determined by immunoblot analyses.gp78 mediates CD82 ubiquitination and degradation [35]. We found
that gp78 expression was not increased in NSCLC cells expressing
mutant EGFR in comparisonwith H1299 cells (Fig. 3a). Moreover, treat-
ment of MG132, a proteasome inhibitor, did not increase CD82 expres-
sion in H1650 cells and H1299 derivatives (Fig. 3b–c). Inhibiting protein
transport from the endoplasmic reticulum to the Golgi apparatus with
brefeldin A apparently reduced the levels of both EGFR and CD82. The
addition of MG132 restored EGFR expression but had little effect on
CD82 expression (Fig. 3d). Additionally, we found that chloroquine, apressesmutant EGFR expression. (a)H1299-vector andH1299-EGFR cellswere transfected
ted with or without EGF (10 ng/ml) for 10 min. The levels of indicated proteins (or phos-
d H1299-Del cells were transfected with a CD82-expressing vector, and the levels of the
munoblot analyses. (c) H1299-EGFR, H1299-L858R, and H1299-Del cells were transfected
2 μM) 8 h before the cell harvests. The levels of indicated proteins (or phosphorylation) in
Fig. 3.Gp78/proteasome and lysosome-mediated protein degradation are not involved in the differential regulation of CD82 in NSCLC. (a) Expression levels of gp78 and actinwere exam-
ined in cell extracts prepared from regularly cultured H1299 derivatives or fromNSCLC cell lines by immunoblot analyses. (b and c) Expression levels of CD82 and actinwere examined in
cell extracts prepared from regularly cultured H1299 derivatives or fromNSCLC cell lines treatedwith orwithoutMG132 (20M, 16 h). (d) Expression levels of EGFR, CD82, and actinwere
examined in cell extracts prepared fromH1299 derivatives treatedwith orwithout brefeldin A (10M) andMG132 (20M) for 16 h. (e) Expression levels of CD82 and actinwere examined
in cell extracts prepared from H1299 derivatives treated with or without chloroquine (CQ, 100 M) for 16 h.
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and H1299-EGFR cells but failed to increase the expression of CD82 in
H1299-L858R and H1299-Del cells (Fig. 3e). These data indicated that
both gp78/proteasome and lysosome-mediated degradation pathways
were not participated in the CD82 down-regulation in mutant EGFR-
expressing NSCLC cells.3.6. NSCLC cells expressing mutant EGFR show increased CD82 exportation
through the exosome pathway
CD82 is present in the exosomes [33]. We found that secreted
exosome CD82 levels in H1299-EGFR, H1299-L858R, and H1299-Del
cell cultures were higher than that of H1299-vector cells (Fig. 4a). The
high exosome/cell CD82 ratios in H1299-L858R and H1299-Del cells in-
dicated that increased exosome exportation might have caused the low
levels of cellular CD82. EGFR, actin, and Flotillin 1 (Flot 1, a protein exists
in exosomes) [36] levels were all increased in the secreted exosome
fractions prepared from H1299-EGFR, H1299-L858R, and H1299-Del
cell cultures, when compared with H1299-vector cells. Interestingly,
heat shock protein 90 (HSP90, a cytoplasmic chaperon molecule) was
nearly undetectable in the exosome fractions, indicating that the expor-
tation of proteins through the exosome is a selective process (Fig. 4b).
Based on the exosome/cell protein ratios, CD82 was exported most
effectively among all the examined proteins.
We also examined CD82 exportation in NSCLC cell lines with endog-
enous EGFRmutation and low cellular CD82 expression. The presence of
CD82 in exosomes secreted fromH1650 cells indicated the active expor-
tation of this protein (Fig. 4c). Additionally, CD82was better detected in
the exosomes but not in the cellular fraction of H1975 cells. This phe-
nomenon was more evident in the TsA-treated H1975 cells (Fig. 4d).
These data indicated that despite the low expression of CD82 protein
in H1650 and H1975 cells, the residual CD82 was actively exported
through the exosome pathway.3.7. Transgenic (Tg)micewith surfactant protein A (SP-A) promoter-driven
mutant EGFR expression develop LAC
Tg mice preferentially expressing EGFR-L858R or exon 19 deletion
mutant in lung tissues through the SP-A promoter were generated
(Fig. 5a–b). Four lines of Tg mice (LR-D and LR-E from L858R mutant,
Del-A and Del-C from exon 19 deletion mutant, respectively) with dif-
ferent mutant EGFR expression levels were selected for further charac-
terization (Fig. 5c). Mouse lines (LR-D and Del-A) with higher Tg EGFR
expression levels also had higher incidence of tumor development
(Table 2). Histopathology examination conﬁrmed that all tumors were
adenocarcinomas (Fig. 5d). Tumors developed in the lungs of mutant
EGFR-Tg mice were positive in SP-C expression, indicating their type II
lung alveolar cell origin (Fig. 5d). The correlation between tumor inci-
dence and EGFRmRNA levels suggested that a threshold level ofmutant
EGFR expressionmight be essential for the development of lung cancers
in Tg mice.3.8. EGFR over-expression associated with CD82 down-regulation in the tu-
mors of mutant EGFR-Tg mice
We found that themutant EGFRs in Tgmicewere expressed initially
(6-week of age) at levels similar to, or lower than the endogenous
mouse EGFR in age/gender-matched non-Tg control mice (Fig. 6a).
The levels of CD82 andpEGFRwere also not evidently different between
mutant EGFR-Tg and non-Tg control mice (Fig. 6a). Then we examined
the EGFR expression in tumor tissues from 18-month old Tg mice and
normal lung tissues from age/gender-matched non-Tg control mice,
respectively. We found that tumor tissues from Del-A and LR-D all
expressed much higher levels of EGFR in comparison with the lung tis-
sues of the control mice (Fig. 6b–c). To conﬁrm this observation, we ex-
amined the expression of mutant EGFRs by immuno-histochemical
(IHC) staining using the EGFR-L858R or exon 19 Del mutant-speciﬁc
Fig. 4.Mutant EGFR-harboring NSCLC cells export CD82 through exosomes excessively. (a and b) Cellular and exosome fractions of H1299 derivatives were prepared as described in the
Material andmethods. The proteins of interest were examined by immunoblot analyses. The intensity of protein signals was determined and presented as numerical numbers, setting the
level of H1299-vector as 1. The relative exosome/cell (E/C) CD82 ratioswere calculated, taking the loading proportions of exosome/cell fractions into account. (c) The proteins of interest in
the cellular extracts and exosome samples of H1299,H1650, andH1975 cellswere examined by immunoblot analyses. (d)H1975 cellswere treatedwith orwithout TsA (100 nM) for 24h.
The proteins of interest in the cellular and exosome fractions of treated cells were examined by immunoblot analyses. The ratio of corresponding exosome/cell samples subjected to the
analyses is 3:1.
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oped in Tg mice, 85% (34/40) in Del-A (Fig. 6d) and 89% (58/65) in
LR-D mice (Fig. 6e), showed over-expression of mutant EGFR when
compared with the adjacent lung tissues which also harbored the
mutant EGFR gene. The speciﬁcity of the EGFR-L858R or exon 19 Del
mutant-speciﬁc antibody had been veriﬁed by immunoblotting
(Fig. 7a–b).
In addition, tumor tissues frommutant EGFR-Tgmice also had lower
levels of CD82 in comparison with the normal lung tissues (Fig. 6b–c).
Moreover, we found that c-Cbl, but not GAK, expression levels were
decreased in tumor tissues of Tg mice (Fig. 8a–b). Consistent with this
observation, c-Cbl expression levels were also lower in NSCLC cell
lines with EGFRmutation (Fig. 8c). The collective data showed that mu-
tant EGFR over-expression, associated with the loss of EGFR negative
regulators such as CD82 and c-Cbl, frequently occurred during the de-
velopment of mutant EGFR-driven LAC.
3.9. EGFR over-expression associateswith CD82 down-regulation in human
LAC
Immunoblot analyses for EGFR and CD82 on the paired tumor and
non-tumor lung tissues from 23 LAC patients (12 with WT EGFR, and
11 with mutant EGFRs) were performed. Representative cases are
shown for patients with WT EGFR (Fig. 9a) and mutant EGFRs
(Fig. 9b). The expression levels of EGFR and CD82 in the tumor tissue
(T) compared with the paired non-tumor lung tissue (N) were counted
as T/N ratio according to the immunoblot study. The T/N ratio data isshown in Table 3. Similar to the tumors of the mutant Tg mice, for the
11 human LAC tumors with mutant EGFRs, all of them (100%) had
EGFR over-expression andmarked down-regulation of CD82. Only 3 tu-
mors had CD82 T/N ratios higher than 0.3. For the 12 LAC tumors with
WT EGFR, although most of the tumors also had EGFR over-expression
(10/12, 83.3%) and CD82 down-regulation (9/12, 75%), the extent of
EGFR over-expression and CD82 down-regulation was much weaker,
with no tumor having a CD82 T/N ratio lower than 0.3. This difference
in CD82 down-regulation was statistically signiﬁcant (p = 0.0003) be-
tween tumors with WT and mutated EGFR. When combining the T/N
ratio data of EGFR and CD82 in a scatter plot ﬁgure (Fig. 9c), it clearly
demonstrates the separation of these two groups of patients, with
only a small number of overlapping cases.
4. Discussion
Mutations at the EGFR kinase domain promote EGFR tyrosine phos-
phorylation in the absence of ligand stimulation [8,9]. Phosphorylation
ofWT EGFR leads to receptor internalization, ubiquitination, and degra-
dation [1]. However, hyper-phosphorylated mutant EGFRs are equally
or more stable in comparison with the WT receptor [8,10,11]. CD82, c-
Cbl, and GAK are molecules involved in EGFR down-regulation [13,14,
25,27]. Our results showed that c-Cbl and CD82, but not GAK, were
expressed at lower levels in NSCLC cells harboring EGFR mutations
and in lung cancer tissues of mutant EGFR Tg mice. Many other mole-
cules also participate in EGFR down-regulation. Breast tumor kinase
(BRK, also named PTK6) inhibits EGFR down-regulation [37], partially
Fig. 5. SP-A promoter-driven mutant EGFR expression induces lung cancer in Tg mice. (a) A schematic illustration of the construction of the SP-A-driven mutant EGFR Tg vectors. (b) The
expression of Tg EGFRmRNAwas examinedbyRT-PCR inRNA samples isolated frommajor visceral organs of Tg and from controlmice. (c) Theexpression of TgEGFRmRNAwas examined
by RT-PCR in RNA samples isolated from the lung tissues of indicated mouse lines. (d) The expression of surfactant protein C (SP-C) or EGFR-Del in tumor (T) and adjacent normal tissue
(N) was examined by IHC in the consecutive lung sections from a Del-A Tg mouse.
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and pleckstrin homology domain-containing protein), a molecule that
prevents EGFR degradation [38,39]. Caveolin-1 has also been shown to
affect EGFR down-regulation [27]. Nevertheless, we did not observed a
signiﬁcant difference in BRK and caveolin expression among NSCLC
cell lines with or without EGFR mutations (data not shown). Therefore,
we did not include these 2 molecules in the current study.
In previous studies, the stability of mutant EGFRs is attributed to
their resistance to c-Cbl-mediated ubiquitination and degradation [10,
11]. Our results suggested that reduction of CD82 and/or c-Cbl may
have also contributed to the stabilization of mutant EGFRs. Over-
expression of WT EGFR increased CD82 level and over-expression of
mutated EGFRs decreased it. This featuremay contribute to the reported
different oncogenicity between WT and mutant EGFRs [12]. In the 23
human LAC tumors we have examined, majority of tumors with WT
EGFR still had CD82 expression levels lower than those in adjacent
non-tumor lung tissues; however, the T/N ratio of CD82was signiﬁcant-
ly higher in tumors withWT EGFR than thosewith EGFRmutation (p=Table 2
Lung adenocarcinoma in non-transgenic and EGFR mutant-transgenic mice.
Age 6 months 12 months 18 months 24 months
Mouse line Tumor incidence (%)
Non-Tg 1/14 0/16 1/18 2/16
L858R-D nd 6/22 8/15 13/14
L858R-E nd 1/21 2/25 3/16
Del-A 5/14 13/18 10/10 nd
Del-C nd 1/22 5/22 8/21
Abbreviations: non-Tg, non-transgenic; nd, not determined.0.0003). This result is consistentwith our data fromNSCLC cell lines and
Tg mice. Since human LAC tumors have a heterogeneous genetic back-
ground and involved multiple oncogenic pathways, it could explain
why not all human LAC tumors with WT EGFR showed CD82 over-
expression.
CD82 level is decreased in various types of cancer and its expression
is regulated at multiple levels [15,17,18]. Three NSCLC cell lines (H1975,
PE089, and HCC827) with low CD82 protein expression also showed
low CD82 mRNA levels. TsA increased CD82 expression in H1975 cells,
suggesting that histone acetylation-mediated chromatin remodeling
participated in regulating CD82 gene expression in this cell line.
H1650 cells showed low CD82 protein expression with an mRNA level
higher than that of H1299 cells, suggesting the existence of post-
transcriptional regulatory mechanisms. We found that H1299-L858R
and H1299-Del cells exported higher proportions of CD82 through
exosomes than did H1299-vector and H1299-EGFR cells. Additionally,
H1650 and H1975 cells exported CD82 excessively through exosomes
despite their low cellular CD82 levels. These results indicated that the
ability to actively export CD82 protein is a common mechanism in
cells with mutated EGFR regardless of their overall CD82 expression
levels. However, increasing exportation of CD82 may also facilitate the
exportation of CD82-interactingmolecules, such as receptor tyrosine ki-
nases and integrin-associated molecules. The exosome has been sug-
gested to play a role in eliciting immune responses against tumors
[40]. Reduction of potential tumor antigen exportation through silenc-
ing CD82 gene expression could be the ultimately selected mechanism
during cancer development.
In this study, Tg mice at 6 weeks of age expressed mutant EGFR at
levels similar to, or even lower than, the age/gender matched control
mice (the endogenous mouse EGFR). But by the time of tumor
Fig. 6.Over-expression of EGFR is associatedwith down-regulation of CD82 in lung cancer tissues inmutant EGFR Tgmice. (a) Lung tissue extracts from 6-wk old control (non-Tg)mice or
mutant EGFR-Tgmicewere analyzed for EGFR, CD82 and pEGFR expression by immunoblot analyses. (b and c) The same immunoblot analyseswere also performed for lung tumor tissues
from 1.5-year old, male Del-A Tg mice and 1.5-year old, male LR-D Tg mice and compared with the lung tissues from age- and gender-matched control mice. (d) Immunohistochemical
stain demonstrated that 85% (34/40) of the lung tumor tissues fromDel-A Tgmice had over-expression ofmutant EGFR-Del protein (right), andonly 6 Tgmicewerenegative (left) (200×).
(e) Immunohistochemical stain demonstrated that 89% (58/65) of the lung tumor tissues fromLR-DTgmicehad over-expression ofmutant EGFR-L858Rprotein (right), and only 7 Tgmice
were negative (left) (200×).
Fig. 7. Tg EGFR is over-expressed in tumor tissues. (a) The expression of Tg EGFR-Del was examined by immunoblotting using a EGFR-Del-speciﬁc antibody. The protein samples were
isolated from the major visceral organs of a Del-A Tg mouse. (b) The lung tissue extracts from control, L858R-D, L858R-E, and Del-A mice were examined by immunoblotting using an
EGFR-L858R- or EGFR-Del-speciﬁc antibody.
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Fig. 8. Cbl expression is decreased inmutant EGFR-containing cell lines and lung cancers. (a and b) The same panels of tissue extracts used in Fig. 4b and c were subjected to immunoblot
analyses using the indicated antibodies. (c) Expression levels of c-Cbl, GAK, and actinwere examined in cell extracts, whichwere prepared fromNSCLC cell lines, by immunoblot analyses.
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expression of mutant EGFRs. The late development of LAC in these ani-
mals (after 6 months of age) suggested that other synergistic mecha-
nisms were involved in the tumorigenic process. Decreasing CD82
expression could be one of the mechanisms that promoted mutant
EGFR over-expression in Tgmice.We also found that CD82 showed bet-
ter suppressive effects on mutant EGFR expression than on WT EGFR.
Therefore, down-regulation of CD82 could be a critical step in EGFR
mutation-induced lung cancer. The study on human LAC tumor tissues
from patients with or without EGFR mutation also demonstrated a
stronger down-regulation of CD82 in patients with mutant EGFRs. The
above data is supportive for our assumption that reduction of CD82
was associated with over-expression of EGFR protein in lung cancer
triggered by mutant EGFR. We have demonstrated that despite the
low expression of CD82 protein in H1650 and H1975 cells, the residual
CD82 was still actively exported through the exosome pathway. Thus,
for assessment of CD82 expression, the level of CD82 in serum
exosomes may not be similar to the LAC tumor tissue.Fig. 9. EGFR over-expression associateswith CD82down-regulation in human lung adenocarcin
11 with mutant EGFRs) and paired non-tumor lung tissues (N) were examined for EGFR and C
malized by the actin levels of the individual samples. (a) Paired tumor and non-tumor tissue sam
tant EGFRs are shown. (c) The expression levels of EGFR and CD82 in the tumor tissue (T) comp
immunoblot study and shown in the scatter plot ﬁgure.5. Conclusion
The present study revealed that down-regulation of EGFR negative
regulators, such as CD82, could be the mechanism facilitating the
over-expression of EGFR in LAC with EGFR mutation. Since CD82 is
also involved in regulating other receptor (or non-receptor) tyrosine ki-
nases [15,17,18], the loss of CD82may lead to the activation of multiple
oncogenic pathways. Therefore, the down-regulation of CD82 could be a
critical step involved in the stronger tumorigenic activity triggered by
EGFR mutations. Up-regulation of the CD82 level may become a prom-
ising new treatment strategy for LAC. Whether CD82 down-regulation
is involved in the drug resistance to EGFR inhibitors is also worthy of
further study.Conﬂict of interest
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aredwith the paired non-tumor lung tissue (N)were counted as T/N ratio according to the
Table 3
Expression of EGFR and CD82 in the 23 human lung adenocarcinoma tumor and paired
non-tumor tissues.
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T/N ratio T/N ratio T/N ratio T/N ratio
1 0.353 5.664 1 0.168 287.758
2 0.323 0.524 2 0.273 6.805
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T/N ratio: the ratio of the protein expression (determinedby immunoblot) between tumor
tissue and paired non-tumor tissue. WT, wild type; MT, mutant.
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